Need Help?

Longitudinal sequencing of a recurrent paediatric high grade neuroepithelial tumour

We have studied a unique case of astroblastoma arising in a 6 year-old girl, with multiple recurrences over a period of 10 years, with the pathognomonic MN1:BEND2 fusion 11 surgical samples from either fresh frozen of paraffin embedded material and 1 blood sample were subjected to Illumina short read whole exome sequencing using Agilent SureSelect whole exome v4. Data is provided as 15 BAM files aligned to hg19 with bwa.

Request Access


HUMAN GENETIC DATA ACCESS AGREEMENT FOR INSTITUTIONSBetween:(1) The Institute of Cancer Research: Royal Cancer Hospital of 123 Old Brompton Road, London SW7 3RP, UK (“ICR”); and(2) [ please insert the legal name and address of your institution ] (the “Recipient”).In response to the Recipient's request for access to the Data (as set out in Appendix A), ICR and the Recipient agree as follows:1Definitions1.1“ICR sequencing” shall mean the project undertaken by ICR to identify genetic sequence variants and mutations in paediatric High Grade Gliomas;1.2 “Data” shall mean all and any human genetic data obtained from ICR sequencing including the age, sex and tumour pathology of a Data Subject. Explicitly, Data does not include samples or biological materials;1.3 “Data Subject” shall mean the person (irrespective of state of health) to whom Data refers and who has been informed of the purpose for which the Data is held and has given his/her informed consent thereto;1.4 “Intellectual Property” means (i) patents, designs, trade marks and trade names (whether registered or unregistered), copyright and related rights, database rights, know-how and confidential information; (ii) all other intellectual property rights and similar or equivalent rights anywhere in the world which currently exist or are recognised in the future; and (iii) applications, extensions and renewals in relation to any such rights;1.5 “Registered User” shall mean a Researcher (or an individual conducting Research under the direct supervision of that Researcher) that is employed by the Recipient and is bound by confidentiality and non-use obligations in respect of Data and who has signed this Agreement and has received acknowledgement of its acceptance. For the avoidance of doubt, “Registered User” may also include students of the Recipient, visiting academics, contractors, sub-contractors or independent consultants provided that any such individual is bound by confidentiality and non-use obligations no less onerous then those binding the Recipient’s employees;1.6 “Research” shall mean research undertaken by the Recipient that seeks to advance the understanding and treatment of cancer and closely related diseases, and work on statistical methods that may be applied to such Research as set out in ;1.7“Researcher(s)” shall mean an individual or individuals carrying out Research who:(a) in the case of an individual seeking access to Data held solely under the control of ICR, has authored a relevant peer-reviewed article that ICR can locate on PubMed and who is still working in the field; or(b) in the case of an individual seeking access to Data held as part of a wider consortium, is a successful applicant to the consortium data access committee.2Purpose2.1The Recipient agrees to use Data only for Research.3 Confidentiality3.1 The Recipient agrees to preserve, at all times, the confidentiality of Data pertaining to identifiable Data Subjects. In particular, the Recipient undertakes not to use, or attempt to use the Data to deliberately compromise or otherwise infringe the confidentiality of information on Data Subjects and their right to privacy. Recipient or Registered Users will not use Data either alone or in conjunction with any other information in any effort whatsoever to establish the individual identities of any Data Subject from whom Data were obtained.4 Data Protection4.1 The Recipient agrees that it, and its Registered Users, are covered by and shall comply with the obligations contained in the Data Protection Act 1998 as amended from time to time, or equivalent national provisions no less onerous then those contained in the Data Protection Act. In particular, the Recipient shall be responsible for ensuring that Registered Users understand and will comply with their duties under such legislation in relation to the handling, storage and use of Data and the rights of Data Subjects.4.2 The Recipient agrees that it, and its Registered Users, shall not analyse or make any use of the Data in such a way that has the potential to:(a) lead to the identification of any Data Subject; or(b) compromise the anonymity of any Data Subject in any way.5 Access and Governance5.1 The Recipient agrees that it shall take all reasonable security precautions to keep the Data confidential, such precautions to be no less onerous than those applied in respect of the Recipient’s own confidential information.5.2 The Recipient agrees to only give access to Data, in whole or part, or any material derived from the Data, to a Registered User. The Recipient agrees that before it gives any Registered User access to Data, it shall first show the Registered User a copy of this Agreement and shall inform the Registered User that he or she must comply with the obligations contained in this Agreement and sign up to the provisions of this Agreement in the form set out at the end of this Agreement. The Recipient shall provide ICR with a copy of the Registered User’s acceptance form within thirty (30) days of the date of acceptance by the Registered User.5.3 The Recipient agrees that it shall only give Registered Users that are not Researchers (including but not limited to students or new researchers to the field) access to the Data if they are supervised by a Researcher who will take responsibility for such Registered Users’ use of the Data.5.4 ICR reserves the right to request and inspect data security and management documentation to ensure the adequacy of data protection measures in countries that have no national laws comparable to that pertaining in the European Economic Area (EEA).6Errors6.1The Recipient agrees to notify the CGP of any errors detected in the Data.7Data reissue7.1 The Recipient accepts that Data will be reissued from time to time, with suitable versioning. If Data is reissued at the request of sample donors and/or as the result of other ethical scrutiny, the Recipient agrees to destroy all earlier versions of the Data.8Intellectual Property8.1The Recipient recognises that nothing in this Agreement shall operate to transfer to the Recipient or its Registered Users any Intellectual Property rights in or relating to the Data.8.2The Data shall at all times remain the property of ICR or of ICR’s designated assignee. Recipient shall retain title to any Intellectual Property made through the Recipient’s use of the Data, except to the extent such Intellectual property incorporates the Data.8.3 The Recipient and its Registered Users shall have the right to develop Intellectual Property based on comparisons with their own data.9Publications9.1 The Recipient agrees to acknowledge in any work based in whole or part on the Data, the published paper from which the Data derives, the version of the Data, and the role of the CGP and its funders in its distribution. The Recipient agrees to use the acknowledgement wording provided for the relevant Data in its publication. The Recipient will also declare in any such work that those who carried out the original analysis and collection of the Data bear no responsibility for the further analysis or interpretation of it by the Recipient.10Termination of Agreement10.1 This Agreement will terminate immediately upon any breach of the provisions of this Agreement by the Recipient or by the Recipient’s Registered Users.10.2The Recipient accepts that the changing ethical framework of human genetic research may lead to: (i) alteration to the provisions of this Agreement, in which case the Recipient may accept such alterations or terminate this Agreement; or (ii) the withdrawal of this Agreement in extreme circumstances.10.3 Either party shall have the right to terminate this Agreement with immediate effect upon giving written notice of termination to the other party.10.4 In the event that this Agreement is terminated in accordance with this Clause 10 the Recipient shall return or destroy all Data at the direction of ICR.11Costs11.1 The Recipient acknowledges that ICR shall incur costs in providing the Data to the Recipient, including but not limited to administrative costs and the cost of obtaining appropriate data storage devices. The Recipient agrees to pay, on the request of ICR, such reasonable costs as ICR may incur in providing the Data, within thirty (30) days of ICR making such a request for payment.12 Legal statement12.1The Recipient acknowledges that ICR and all other parties involved in the creation, funding or protection of the Data:(a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of the Data; and(b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of the Data, or from the unavailability of, or break in access to the Data for whatever reason.12.2 The Recipient understands that all the Data is protected by copyright and other intellectual property rights, such that duplication or sale of all of or part of the Data on any media is not permitted under any circumstances, except with the prior written consent of ICR.13 Governing Law13.1 This Agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this Agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts. AGREED by the parties through their authorised signatoriesINSTITUTE OF CANCER RESEARCHAuthorised Signature:Name:Title:Date:RECIPIENT INSTITUTION:Recipient Name:Address:Telephone No:Email:Researcher Signature:Name:Title:Date:Registered User Signature:Name:Title:Date:Please send completed forms to:Chris Jones PhD FRCPathLeader, Glioma TeamDivisions of Molecular Pathology and Cancer TherapeuticsThe Institute of Cancer Research15 Cotswold Road, Sutton, Surrey SM2 5NG, UKTel: +44 (0)20 8722 4416 | Email: complies with the requirements of the Data Protection Act 1998 with regard to the collection, storage, processing and disclosure of personal information and is committed to upholding the Act's core Data Protection Principles. Information collected under the Agreement will be used for the purposes of maintaining the Agreement, and may be used for statistical reporting.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001002432 Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00002008416 bam 9.5 GB
EGAF00002008417 bam 13.6 GB
EGAF00002008418 bam 5.2 GB
EGAF00002008419 bam 7.2 GB
EGAF00002008420 bam 13.0 GB
EGAF00002008421 bam 8.2 GB
EGAF00002008422 bam 11.5 GB
EGAF00002008423 bam 7.5 GB
EGAF00002008424 bam 3.6 GB
EGAF00002008425 bam 12.1 GB
EGAF00002008426 bam 5.7 GB
EGAF00002008427 bam 5.4 GB
EGAF00002008428 bam 7.3 GB
EGAF00002008429 bam 7.1 GB
EGAF00002008430 bam 5.5 GB
15 Files (122.4 GB)